Novo Integrated Sciences Provides Update on Certain Current Actions and Events - Seite 2

To date, the Company is compliant with all terms, conditions, and waivers related to the SPA and RC Note and is awaiting the Buyer to provide the Company with approval of initial drawdown of funds.

• All Parties Actively Pursuing Monetization of One Billion Dollar Gold-backed Bond. As previously disclosed, on September 27, 2023, Novo and Blacksheep Trust (“Blacksheep”) entered into a Master (Asset Transfer) Agreement in which Blacksheep agreed to transfer to the Company certain collateral equal to $1 billion and controlled by Blacksheep (the “Collateral”). On December 13, 2023, Blacksheep filed a UCC-3 Financing Statement Amendment with the State of New York, providing partial assignment of a $1 Billion Dollar Gold-Bullion backed Bond (the “Bond”) to Novo. The Gold-backed Bond is a 20-year instrument earning 12.5 percent simple interest per annum. The UCC-3 filing provides for the partial assignment and transfer of the full face-value of the Bond to Novo for a maximum term of 15-years without the benefit of annual interest.
  
  The Company is aggressively pursuing monetization of the Bond with internationally based facility providers.

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.